Vogenx Inc.
VOGX
NASDAQ19.75
USD
+4.00
- -
ISIN
US92859A1060
CUSIP
92859A106
Return %
Stock
S&P500
1Y
51.92
19.43
3Y
51.92
76.01
5Y
51.92
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3901 Barrett Drive, Suite 300 Raleigh NC United States of America 27609
- IPO Date
- Aug 12, 2026
- Website
- vogenx.com
- Similar Companies
- Business
- Vogenx Inc. is a biotechnology company focused on the discovery, development, manufacturing and commercialization of nucleotide-based therapies and related platforms for human health. The company provides a portfolio of antisense, oligonucleotide, and RNA-targeted therapeutic products and services, along with platform-enabled research, development, and manufacturing capabilities designed to support clinical and commercial programs. Vogenx operates across discovery, preclinical and clinical development, manufacturing, and regulatory support, delivering integrated solutions that encompass product design, synthesis, formulation, delivery and quality control. Main products and services include: - Nucleotide-based therapeutics development and manufacturing; antisense oligonucleotides; RNA-targeted therapies; chemical modification and conjugation for enhanced stability and delivery; process development and analytical characterization; clinical-grade synthesis and GMP manufacturing; formulation development and optimization; preclinical and translational services; regulatory documentation support and quality assurance. - Platform offerings and services including nucleic acid synthesis, scalable production, custom oligonucleotide design, sequence optimization, and delivery platform collaborations; technical services for target validation, assay development, and biomarker analysis; outsourcing of manufacturing and supply chain management for clinical and commercial programs. - Supporting tools and infrastructure for research collaboration, project management, data generation, and documentation to accelerate product pipelines from concept to regulatory approval. Latest major company changes include: - Strategic partnerships and alliances with biopharma and academic partners to expand pipeline and accelerate clinical development. - Acquisitions or minority investments in adjacent platforms or technology platforms to enhance capabilities in delivery, synthesis, or analytical services. - Launch of new product lines or expanded service offerings, including expanded GMP manufacturing capacity and enhanced formulation capabilities. - Operational expansions such as facility upgrades or new regional manufacturing footprints to better serve global clients. - Company reorganization or name changes tied to strategic pivots or corporate restructuring within the last 1-2 years. Industry context and segments: - Industry: Biotechnology, molecular therapeutics, and nucleic acid therapeutics. - Segments: Therapeutics development and manufacturing services, platform technologies, contract development and manufacturing organization (CDMO) capabilities, and research services. - Target markets: Biopharmaceutical companies, research institutions, and clinical development programs seeking nucleotide-based therapies. - Geographic operations: Global footprint with facilities and partnerships that support regional and international customers, including North America, Europe, and Asia-Pacific regions. - Corporate structure: Independent company, with potential parent or subsidiary relationships through partnerships or strategic collaborations. Founding year and headquarters: - Founded in the early 2020s; headquartered in a biotech hub, with R&D and manufacturing operations located in key strategic regions to enable rapid development and scalable production.
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
Vogenx Announces Closing of Initial Public Offering
Vogenx Announces Pricing of Initial Public Offering